Opinion in Japan

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

3G handsets: Japan will invade Europe

Published By Datamonitor
28 Mar 2001
CommentWire
CommentWire

3G mobiles: the death of a standard

Published By Datamonitor
01 Feb 2001
Expert View
Expert View

AAN 2012: BG-12 remains main focus of Biogen's extensive MS portfolio

Biogen used the platform of the 64th American Academy of Neurology Annual Meeting to provide updates on its extensive MS portfolio. Much time was devoted to its Phase III pipeline candidate BG-12, which looks set to be the next agent to enter the market, as well as the presentation of long-term safety data for Tysabri.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: Novartis presents new data in an attempt to boost confidence in long-term use of Gilenya

In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: pooled data support future use of late-stage MS and epilepsy products

Teva, Eisai, and GlaxoSmithKline all used the opportunity of this year's American Academy of Neurology Annual Meeting to showcase pooled analysis of their late-stage pipeline candidates. While not groundbreaking, the positive data for laquinimod (MS) and perampanel and Potiga (epilepsy) will bolster physician confidence and position the drugs well in their respective markets.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: research shows value of early disease identification, but caution in treatment is advised

At AAN 2012, Merck Serono presented data from a long-term study showing that early Rebif treatment significantly reduced the clinical progression of multiple sclerosis. However, early intervention should be used cautiously to avoid unnecessary treatment.

Published By Datamonitor
03 May 2012
Expert View
Expert View

Abenomics spurring Japanese wealth M&A

Divergent views on Japan are resulting in motivated sellers and willing buyers. Societe Generale has become the latest foreign player to sell out of Japan's wealth management market, but Datamonitor doubts it will be the last.

Published By Datamonitor
26 Jul 2013
Expert View
Expert View

Abercrombie & Fitch: will it be another Gap story?

US casualwear brand Abercrombie & Fitch opened its first store outside North America on March 22 in London. The company plans to open flagship stores in other European cities, as well as in Japan, as it grows into a global brand. The question is whether it will achieve success with its typically American style or end up with Gap's core problem - being unable to adapt to different markets.

Published By Datamonitor
22 Mar 2007
CommentWire
CommentWire

Aggreko: World Cup confirms the power of rental

Aggreko continues to impress as a company on the up: its rising share price over the last five years bears testament to the success of the organization. As power demand increases across the world, often in geographically remote locations, concerns over security supply issues remain, and rental power companies look set to stay successful. <BR />

Published By Datamonitor
12 Jun 2002
ResearchWire
ResearchWire

AIDS: European incidence falling 3.9% per year

Published By Datamonitor
09 Jul 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.